|drug755||Chiropractic care (one visit) Wiki||0.50|
|drug2637||Primary care Wiki||0.50|
|drug3334||Tele-yoga therapy Wiki||0.50|
There are 4 clinical trials
The study aims to evaluate the working environments of individuals working from home during the covid-19 outbreak and the effect of the working environments on their musculoskeletal system. The study will include 500 people between the ages of 18-65 who works from home (works in the office before isolation) as a part of Covid-19 isolation measure. The working environment of the individuals participating in the study will be evaluated with The Rapid Office Strain Assessment (ROSA). Musculoskeletal symptoms will be analysed by using the Standardised Nordic Questionnaries (NMQ). Pain will be analysed by using Visual Analogue Scale (VAS)
Description: The working environment of the individuals participating in the study will be evaluated with The Rapid Office Strain Assessment (ROSA).Measure: The Rapid Office Strain Assessment (ROSA) Time: 30 minutes
Description: The NMQ can be used as a questionnaire or as a structured interviewMeasure: The Standardised Nordic Questionnaries (NMQ) Time: 15 minutes
Description: Pain will be analysed by using Visual Analogue Scale (VAS)Measure: Visual Analog Scale (VAS) Time: 2 minutes
Covid-19 outbreak and lockdown measures raised significant concerns over clinical management of chronic pain patients around the world. Patients with chronic musculoskeletal pain (CMSP) are at high risk of physical disability, psychological distress, and poor quality of life. Analgesic medications were main management during lockdown, but opioid-related concerns have prompted to find immediate alternatives. Present study was undertaken to determine whether patients randomized to tele-yoga therapy would experience less pain, disability and improved global health, adherence and satisfaction, compared with patients assigned to usual care.
Description: Pain was assessed using the Brief Pain Inventory (BPI), which rates the severity of pain on 4 items (current, worst, least, and average pain in past week)Measure: Severity of pain Time: From baseline to 6-week post intervention
Description: Interference of pain in 7 areas (mood, physical activity, work, social activity, relations with others, sleep, enjoyment of life) were reported using BPIMeasure: Interference of pain Time: From baseline to 6-week post intervention
Description: 7-point global rating of pain change was used to assess change in painMeasure: Global rating of change in pain Time: From baseline to 6-week post interventiona
Description: 10 point scale was used to assess intervention-specific satisfactionMeasure: Intervention specific satisfaction Time: From baseline to 6-week post interventiona
This is a pragmatic controlled clinical trial taking place in the first phase of COVID-19 lockdown re-opening in Spain. Patients of 52 chiropractic clinics were invited to participate in a pseudo-random order (one out of every three contacted patients) as they were contacted to either schedule an appointment with their current chiropractor or not, depending on the clinic's and the patient's availability. Patients would receive chiropractic in-person care (one or more than one visits) or no care at all, for a two-week period. According to the care received, they were assigned to one of three groups (receiving no care, receiving care once, and more than once). Participants filled an online questionnaire with self-reported outcome-measures at the beginning of the two week period. A follow-up questionnaire was completed 14 days after.
Description: Numerical rating scale (0-10, 0 meaning no pain, 10 meaning worst pain imaginable)Measure: Pain intensity Time: 14 days
Description: Likert Scale from better (1) to worst (4) outcomes, 1: occasionally, 4: constantlyMeasure: Pain frequency Time: 14 days
Description: Likert Scale of self-perceived improvement, from better (1) to worst (5) outcomes, 1: much better, 5: much worseMeasure: Pain evolution Time: 14 days
Description: Validated subscale form the Brief Pain Inventory, 6 categories from 0 to 10 each, the lower, the better outcomes, out of a minimal of 0 and total of 60.Measure: Pain interference Time: 14 days
Description: Validated questionnaire. Short version 4 items, Likert scale from 0 to 4, lowest score (0) better outcomes, highest score (16) worst outcomesMeasure: Pain Catastrophizing Scale Time: 14 days
Description: Validated questionnaire. Short version 11 items, Likert scale from 1 to 4, lowest score (11) better outcomes, highest score (44) worst outcomesMeasure: Tampa Scale Kinesiophobia Time: 14 days
Description: Validated questionnaire 7 items, Likert scale from 0 to 3, lowest score (0) better outcomes, highest score (21) worst outcomesMeasure: General Anxiety Disorder scale Time: 14 days
Description: Validated questionnaire. Short version 12 items, Likert scale from 1 to 5, lowest score (12) better outcomes, highest score (60) worst outcomesMeasure: Intolerance of Uncertainty Scale Time: 14 days
Description: Validated questionnaire 10 items, Likert scale from 1 to 10, lowest score (10) WORST outcomes, highest score (100) BETTER outcomesMeasure: General Self-Efficacy scale Time: 14 days
Description: Questionnaire, subscale 10 items, Likert scale from 1 to 4, lowest score (1) WORST outcomes, highest score (40) BETTER outcomesMeasure: Fear of Illness and Virus Evaluation Time: 14 days
Worldwide, the COVID-19 pandemic continues to grow. Although COVID-19 mainly affects the lungs and internal organs, musculoskeletal injury from this disease was reported with the presentation of marked elevation in creatine kinase and lactate dehydrogenase levels. Patients with post-acute COVID-19 are considered patients with a post-intensive syndrome (PICS) that results in loss of functional independence. In the physical and rehabilitation medical field, various modalities with therapeutic exercise can be used to manage pain by a physical therapist and psychiatrist. Pain management is particularly important during the COVID-19 pandemic because of the reduced accessibility to hospitals and medical resources.
Description: the characterization of the pain. Total of 24. > 11 neuropathic pain.Measure: Self-reported Version of the Leeds Assessment of Neuropathic Symptoms and Signs Time: Baseline
Description: the characterization of the painMeasure: PainDETEC Time: Baseline
Description: To measure quality of life, grade ranging from 0 (the worst possible health status) to 100 (the best possible health status)Measure: EuroQol-5D Time: Baseline
Description: To measure psychological status. 0-7 = Normal; 8-10 = Borderline abnormal (borderline case), 11-21 = Abnormal (case)Measure: The Hospital Anxiety and Depression Scale Time: Baseline
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports